Duální antiagregační terapie v prevenci mozkového infarktu
| Title in English | Dual antiplatelet therapy in stroke prevention |
|---|---|
| Authors | |
| Year of publication | 2007 |
| Type | Article in Periodical |
| Magazine / Source | Kardiologická revue |
| MU Faculty or unit | |
| Citation | |
| Field | Neurology, neurosurgery, neurosciences |
| Keywords | stroke; antiplatelet therapy |
| Description | Ischemic stroke (CVA) are diseases with high incidence. According to the database IKTA of 2000, the incidence of cerebral infarction (MI) or transient ischemic attack (TIA) is in the 250 to 100 000 inhabitants. The patient has a TIA in the next 90 days to 10% risk of recurrent ischemic stroke, patients with MI have a 90-day risk of recurrence to 7.4% in 5 years the risk is 40%. The aim of antiplatelet therapy to prevent recurrence of these events, however, traditionally used as thienopyridinové aspirin medication (ticlopidine, clopidogrel) have relatively low efficiency (eg ASA, the annual absolute risk reduction of about 1%). Summarizes recent findings on dual antiplatelet therapy, based on recently published studies MATCH, CHARISMA, and ESPRIT. |